Is VKORC1 destiny or just a small risk factor?

VKORC1 encodes vitamin K epoxide reductase, a key enzyme in the vitamin K cycle that activates clotting factors. Common variants (e.g., rs9923231) strongly influence warfarin sensitivity: carriers of the ‘sensitive’ allele require lower doses to avoid bleeding or clotting. However, VKORC1 is not destiny. Warfarin dosing is multifactorial—CYP2C9 genotype, age, body weight, dietary vitamin K intake, and comorbidities all play major roles. Clinical guidelines (e.g., CPIC) recommend using VKORC1 and CYP2C9 genotypes as part of a dosing algorithm, but regular INR monitoring remains essential. The evidence for VKORC1’s impact on warfarin response is strong (human-strong: multiple RCTs and meta-analyses). For other claims—like bone density or vitamin K metabolism—the evidence is weaker and more mechanistic. So while VKORC1 is a significant risk factor, it is not deterministic. A DNA test can inform but never replace clinical monitoring. Overinterpreting a single gene variant as ‘destiny’ ignores the complex reality of pharmacotherapy.